drugset / Trial / NCT00567476

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

NCT00567476

Phase 4 Completed 116 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

This study investigated asthma-related quality of life in Brazilian patients using omalizumab.

Timeline

Start
2007-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omalizumab Monoclonal antibody 150 mg Subcutaneous
Comparator Omalizumab Monoclonal antibody 375 mg Subcutaneous
Comparator Salbutamol Unknown 5 mg Other
Comparator Terbutaline Small molecule 10 mg Other

Indications